Markets Business Research Reports Premium Economy & Finance Law & Policy

Lupin Q2 Results: Profit Beats Estimates, Revenue Up 13%

Lupin's operating profit or Ebitda climbed 42% to Rs 1,308 crore during the September quarter.

Varsha Chandnani

Lupin Ltd.'s Q2 results show a 74% rise in net profit and a 13% increase in revenue, driven by a significant improvement in margins and strong operational performance, surpassing market estimates. (Photo source: company website)

Lupin Ltd.'s consolidated net profit rose 74% in the second quarter of the financial year, beating analysts' estimates.

The company posted a net profit of Rs 852.6 crore in the quarter ended September in comparison to Rs 489.7 crore in the year-ago period, according to an exchange filing on Thursday. Analysts tracked by Bloomberg had estimated a profit of Rs 742 crore.

Lupin Q2 FY25 Earnings Highlights (Consolidated, YoY)

  • Revenue up 13% to Rs 5,672.7 crore versus Rs 5,038.6 crore (Bloomberg estimate: Rs 5,560 crore).

  • Ebitda up 41.7% to Rs 1,308 crore versus Rs 923 crore (Bloomberg estimates Rs 1,203 crore).

  • Margin expands to 23.1% versus 18.3% (Estimate: 21.6%).

  • Net profit up 74% to Rs 852.6 crore versus Rs 489.7 crore (Estimate: Rs 742 crore).

Also Read: Emcure Pharmaceuticals Q2 Results: Profit Jumps 39%, Revenue Up 20%

North America

Lupin's North America sales reached Rs 1,971 crore, a 5.6% increase and accounting for 36% of the company’s global sales. US sales rose to Rs 1,834 crore from Rs 1,776 crore in the year-ago period.

Lupin received 10 abbreviated-new-drug-application approvals from the FDA and launched two new products, bringing its US generics portfolio to 162 products.

Also Read: NHPC Q2 Results: Profit Plunges 37%, Misses Estimates

India

Lupin's India formulation sales reached Rs 2,010 crore, marking an 19% increase and representing 37% of Lupin's global sales. During the first half of the fiscal, the company launched five brands across diabetes, neuro/CNS, gastrointestinal, cardiac and gynae therapies.

Also Read: Cummins India Q2 Results: Profit Beats Estimates, Revenue Rises 31%

Sales in growth markets (Asia–Pacific and Latin America) reached Rs 490 crore, a 12% increase and contributing 9% to Lupin's global sales. Sales in Europe, the Middle East and Africa rose 20% to Rs 569 crore, accounting for 10% of the company's global sales.

Global active-pharmaceutical-ingredient sales rose 9.7% to Rs 294 crore, contributing 5% to the company's global sales.

Shares of Lupin closed 2.52% lower at Rs 2,110.55 apiece on the NSE, compared to a 1.16% decline in the benchmark Nifty 50.

Also Read: Q2 Results Updates: Cummins Profit Rises 37%; NHPC Profit Misses Estimates

Watch LIVE TV , Get Stock Market Updates, Top Business , IPO and Latest News on NDTV Profit.
GET REGULAR UPDATES

RECOMMENDED FOR YOU

NHPC, Lupin, Mahindra & Mahindra, RVNL, Trent Q2 Results Today — Earnings Estimates
timelogo Nov 07, 2024
Lenskart Cuts Losses By 84% To Rs 10.15 Crore, Revenue Up 43% In FY24
timelogo Nov 06, 2024
IndusInd Bank Stake Sale: Societe Generale Offloads Shares Worth Rs 421 Crore
timelogo Oct 25, 2024
M&M Financial Services Q2 Result: Profit Jumps 57% But Misses Estimates
timelogo Oct 22, 2024

POPULAR

1
US Fed Meeting Live: FOMC Cuts Rates By 25 Basis Points To 4.5-4.755, Cites Easing Labour Market Conditions
2
US Federal Reserve Cuts Interest Rate For Second Consecutive Time
3
ED Raids E-Commerce Vendors On Amazon, Flipkart In Foreign Investment Probe (IGNORE)
4
Mahindra Group Eyes Profitability For MLL Express With Focus On Cost Efficiency
5
Sony India FY24 Profit Up 22% To Rs 167 Crore